• Alphamab Oncology secured China CDE clearance to start a Phase III trial of JSKN033 in recurrent or metastatic cervical cancer.
• The study targets patients who failed platinum chemotherapy and PD-1/PD-L1 inhibitors.
• JSKN033 is a subcutaneous fixed-dose combination of a HER2 bispecific ADC (JSKN003) with PD-L1 inhibitor envafolimab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12269728), on August 03, 2026, and is solely responsible for the information contained therein.